IQVIA (NYSE:IQV) Upgraded at StockNews.com

StockNews.com upgraded shares of IQVIA (NYSE:IQV - Free Report) from a hold rating to a buy rating in a research note published on Tuesday morning.

Other analysts also recently issued reports about the stock. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Truist Financial reissued a "buy" rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Robert W. Baird lowered their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. UBS Group reduced their price target on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Finally, Citigroup lowered their price objective on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Trading Down 0.2 %

Shares of IQVIA stock traded down $0.40 on Tuesday, reaching $185.45. 1,215,605 shares of the company were exchanged, compared to its average volume of 1,434,851. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA has a fifty-two week low of $179.28 and a fifty-two week high of $261.73. The firm has a market capitalization of $32.70 billion, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The stock has a fifty day moving average price of $198.24 and a 200-day moving average price of $213.66.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts expect that IQVIA will post 10.84 EPS for the current year.

Institutional Investors Weigh In On IQVIA

A number of large investors have recently added to or reduced their stakes in the stock. Capital Performance Advisors LLP bought a new stake in shares of IQVIA during the 3rd quarter worth $27,000. Synergy Asset Management LLC acquired a new position in IQVIA during the 4th quarter worth $33,000. Avior Wealth Management LLC grew its position in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the fourth quarter worth about $39,000. Finally, Lee Danner & Bass Inc. acquired a new position in shares of IQVIA during the 4th quarter worth about $44,000. Institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.